Biao Dong, Hiroyuki Nakai, Weidong Xiao  Molecular Therapy 

Slides:



Advertisements
Similar presentations
-The methods section of the course covers chapters 21 and 22, not chapters 20 and 21 -Paper discussion on Tuesday - assignment due at the start of class.
Advertisements

How do you identify and clone a gene of interest? Shotgun approach? Is there a better way?
Molecular Tools. Recombinant DNA Restriction enzymes Vectors Ligase and other enzymes.
DNA Technologies (Introduction)
BIO 244: General Microbiology
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Volume 3, Issue 6, Pages (June 2001)
Volume 136, Issue 1, Pages e2 (January 2009)
Molecular Therapy - Methods & Clinical Development
Self-Excising Retroviral Vectors Encoding the Cre Recombinase Overcome Cre- Mediated Cellular Toxicity  Daniel P. Silver, David M. Livingston  Molecular.
Molecular Reconstruction of Sleeping Beauty, a Tc1-like Transposon from Fish, and Its Transposition in Human Cells  Zoltán Ivics, Perry B Hackett, Ronald.
Molecular Therapy - Methods & Clinical Development
Volume 21, Issue 12, Pages (December 2013)
Robert E. White, Richard Wade-Martins, Michael R. James 
Volume 16, Issue 3, Pages (March 2008)
Improved system for helper-dependent adenoviral vector production
Claire Soudais, Sylvie Boutin, Eric J. Kremer  Molecular Therapy 
Volume 2, Issue 4, Pages (October 2000)
Volume 61, Issue 1, Pages S9-S15 (January 2002)
Volume 10, Issue 1, Pages (July 2004)
Molecular Therapy - Methods & Clinical Development
Human Papilloma Virus E6 and E7 Proteins Support DNA Replication of Adenoviruses Deleted for the E1A and E1B Genes  Dirk S. Steinwaerder, Cheryl A. Carlson,
Molecular Therapy - Methods & Clinical Development
Vaccinia virus as a subhelper for AAV replication and packaging
Molecular Therapy - Methods & Clinical Development
Volume 14, Issue 1, Pages (July 2006)
Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells
Molecular Therapy - Methods & Clinical Development
Volume 12, Issue 6, Pages (December 2005)
Volume 2, Issue 3, Pages (September 2000)
Helper virus-mediated downregulation of transgene expression permits production of recalcitrant helper-dependent adenoviral vector  Donna J Palmer, Nathan.
A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors  Qizhao Wang, Zhongren Wu, Junping Zhang, Jenni Firrman, Hongying Wei, Zhengjing.
Molecular Therapy - Methods & Clinical Development
Volume 19, Issue 3, Pages (March 2011)
Volume 9, Issue 3, Pages (March 2002)
Xiuwu Zhang, Chuan-Yuan Li  Molecular Therapy 
Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP.
Retroviral vector–mediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells  Daryoush.
Volume 23, Issue 10, Pages (October 2015)
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Receptor-Targeted Gene Delivery Using Multivalent Phagemid Particles
Volume 16, Issue 5, Pages (May 2008)
Volume 16, Issue 6, Pages (June 2008)
Volume 7, Issue 1, Pages (January 2003)
Volume 15, Issue 2, Pages (February 2007)
Volume 15, Issue 11, Pages (November 2007)
Mathieu Nonnenmacher, Harm van Bakel, Roger J Hajjar, Thomas Weber 
Volume 6, Issue 5, Pages (November 2002)
Volume 22, Issue 4, Pages (April 2014)
Efficient Sleeping Beauty DNA Transposition From DNA Minicircles
Volume 12, Issue 5, Pages (November 2005)
Template Switching by RNA Polymerase II In Vivo
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
Effect of Genome Size on AAV Vector Packaging
Cheryl A. Carlson, Dmitry M. Shayakhmetov, André Lieber 
Volume 4, Issue 6, Pages (December 2001)
Volume 17, Issue 1, Pages (January 2009)
Volume 6, Issue 3, Pages (September 2002)
Development of a Novel Recombinant Adeno-Associated Virus Production System Using Human Bocavirus 1 Helper Genes  Zekun Wang, Fang Cheng, John F. Engelhardt,
Molecular Therapy - Methods & Clinical Development
Volume 20, Issue 6, Pages (June 2012)
Volume 7, Issue 1, Pages (January 2003)
Molecular Therapy - Oncolytics
Thomas Gaj, Benjamin E Epstein, David V Schaffer  Molecular Therapy 
Evidence for Encapsidation of Prokaryotic Sequences during Recombinant Adeno- Associated Virus Production and Their in Vivo Persistence after Vector Delivery 
Volume 9, Issue 4, Pages (April 2004)
Volume 3, Issue 4, Pages (April 2001)
Volume 14, Issue 1, Pages (July 2006)
Molecular Therapy - Methods & Clinical Development
Presentation transcript:

Characterization of Genome Integrity for Oversized Recombinant AAV Vector  Biao Dong, Hiroyuki Nakai, Weidong Xiao  Molecular Therapy  Volume 18, Issue 1, Pages 87-92 (January 2010) DOI: 10.1038/mt.2009.258 Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Illustration of AAV vector genomes. The stuffer fragments were partial sequences of factor VIII gene. The vectors were named according to their rAAV genome size. The DNA fragment used for the probe for Southern blot hybridization was identified, which corresponds to the sequences in the ampicillin-resistant gene. AAV, adeno-associated virus; ampR, an ampicillin-resistant gene, β-lactamase; ITR, inverted terminal repeat sequence; ori, a plasmid replication region of pUC18; ↓, AleI site; *, BamHI site; Δ, SmaI site. Molecular Therapy 2010 18, 87-92DOI: (10.1038/mt.2009.258) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Oversized AAV vectors are inefficient in packaging. rAAV vectors were packaged using AAV5 capsids using triple plasmid transfection method as described in the Materials and Methods section. The resulting rAAV vectors were purified by two rounds of cesium chloride–gradient ultracentrifugation. (a) rAAV vectors in each gradient fraction were quantified by use of Southern dot-blotting. Each dot represented 2 µl of purified vectors from each gradient fraction. The membrane was hybridized with a probe to a region that is identical in all vectors. (b) Detection of capsid proteins by silver staining. A volume of 1 × 1010 viral particles for each vector were used for the silver staining. rAAV, recombinant adeno-associated virus; Std, the standard for quantification of the purified viral genomes; VP1, VP2, VP3, are AAV capsid proteins. Molecular Therapy 2010 18, 87-92DOI: (10.1038/mt.2009.258) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Analysis of the rAAV genome integrity. The size of the single-stranded DNAs packaged in rAAV capsids were analyzed using alkaline agarose gel electrophoresis. After extensive DNaseI treatment, the packaged DNAs from different vectors were resolved on 1% alkaline agarose gel. The membrane was hybridized with a probe specific to the ampicillin-resistant gene. rAAV, recombinant adeno-associated virus. Molecular Therapy 2010 18, 87-92DOI: (10.1038/mt.2009.258) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Rescued rAAV genomes from HeLa cells. HeLa cells were transduced with similar amounts of rAAVs at a multiplicity of infection of 10,000. After 24-hour infection, low-molecular-weight DNAs were extracted and transformed into competent cells. The ampicillin-resistant colonies growing on Luria–Bertani plates were counted for each vector. The experiment was repeated twice. rAAV, recombinant adeno-associated virus. Molecular Therapy 2010 18, 87-92DOI: (10.1038/mt.2009.258) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Summary of the deleted regions in the rescued rAAV genomes for DB7.2. All plasmids rescued from HeLa cells and mouse muscle tissues were analyzed by restriction enzyme digestion and DNA sequencing. The percentage was calculated as dividing the total number of rescued plasmids by the number of classified plasmids. The semi-filled box illustrates missing region from recovered rAAV genome. ampR, an ampicillin-resistant gene, β-lactamase; ITR, inverted terminal repeat sequence; ori, a plasmid replication region of pUC18; rAAV, recombinant adeno-associated virus. Molecular Therapy 2010 18, 87-92DOI: (10.1038/mt.2009.258) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions